Logo image of RVMD

REVOLUTION MEDICINES INC (RVMD) Stock Fundamental Analysis

NASDAQ:RVMD - Nasdaq - US76155X1000 - Common Stock - Currency: USD

36.975  -2.8 (-7.03%)

After market: 36.975 0 (0%)

Fundamental Rating

3

Overall RVMD gets a fundamental rating of 3 out of 10. We evaluated RVMD against 560 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RVMD as it has an excellent financial health rating, but there are worries on the profitability. RVMD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RVMD has reported negative net income.
In the past year RVMD has reported a negative cash flow from operations.
In the past 5 years RVMD always reported negative net income.
RVMD had a negative operating cash flow in each of the past 5 years.
RVMD Yearly Net Income VS EBIT VS OCF VS FCFRVMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M -600M

1.2 Ratios

RVMD's Return On Assets of -23.46% is fine compared to the rest of the industry. RVMD outperforms 74.82% of its industry peers.
Looking at the Return On Equity, with a value of -26.49%, RVMD is in the better half of the industry, outperforming 79.82% of the companies in the same industry.
Industry RankSector Rank
ROA -23.46%
ROE -26.49%
ROIC N/A
ROA(3y)-25.08%
ROA(5y)-24.01%
ROE(3y)-28.89%
ROE(5y)-28.2%
ROIC(3y)N/A
ROIC(5y)N/A
RVMD Yearly ROA, ROE, ROICRVMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RVMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RVMD Yearly Profit, Operating, Gross MarginsRVMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

8

2. Health

2.1 Basic Checks

RVMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RVMD has more shares outstanding
Compared to 5 years ago, RVMD has more shares outstanding
RVMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RVMD Yearly Shares OutstandingRVMD Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
RVMD Yearly Total Debt VS Total AssetsRVMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

RVMD has an Altman-Z score of 13.27. This indicates that RVMD is financially healthy and has little risk of bankruptcy at the moment.
RVMD has a Altman-Z score of 13.27. This is amongst the best in the industry. RVMD outperforms 91.07% of its industry peers.
There is no outstanding debt for RVMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 13.27
ROIC/WACCN/A
WACC9.55%
RVMD Yearly LT Debt VS Equity VS FCFRVMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

RVMD has a Current Ratio of 14.20. This indicates that RVMD is financially healthy and has no problem in meeting its short term obligations.
RVMD's Current ratio of 14.20 is amongst the best of the industry. RVMD outperforms 85.89% of its industry peers.
RVMD has a Quick Ratio of 14.20. This indicates that RVMD is financially healthy and has no problem in meeting its short term obligations.
RVMD's Quick ratio of 14.20 is amongst the best of the industry. RVMD outperforms 85.89% of its industry peers.
Industry RankSector Rank
Current Ratio 14.2
Quick Ratio 14.2
RVMD Yearly Current Assets VS Current LiabilitesRVMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

3

3. Growth

3.1 Past

RVMD shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.58%.
RVMD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-6.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.43%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

RVMD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.33% yearly.
RVMD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 450.85% yearly.
EPS Next Y-34.75%
EPS Next 2Y-20.48%
EPS Next 3Y-10.66%
EPS Next 5Y21.33%
Revenue Next Year350%
Revenue Next 2Y291.95%
Revenue Next 3Y670.52%
Revenue Next 5Y450.85%

3.3 Evolution

RVMD Yearly Revenue VS EstimatesRVMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
RVMD Yearly EPS VS EstimatesRVMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 15 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RVMD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RVMD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RVMD Price Earnings VS Forward Price EarningsRVMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RVMD Per share dataRVMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

A cheap valuation may be justified as RVMD's earnings are expected to decrease with -10.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.48%
EPS Next 3Y-10.66%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RVMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REVOLUTION MEDICINES INC

NASDAQ:RVMD (5/27/2025, 8:00:01 PM)

After market: 36.975 0 (0%)

36.975

-2.8 (-7.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners106.05%
Inst Owner Change5.1%
Ins Owners1.92%
Ins Owner Change2.36%
Market Cap6.89B
Analysts88.42
Price Target74 (100.14%)
Short Float %9.12%
Short Ratio8.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.21%
Min EPS beat(2)-11.25%
Max EPS beat(2)-3.17%
EPS beat(4)1
Avg EPS beat(4)-2.22%
Min EPS beat(4)-11.25%
Max EPS beat(4)8.02%
EPS beat(8)3
Avg EPS beat(8)-3.58%
EPS beat(12)6
Avg EPS beat(12)0.14%
EPS beat(16)7
Avg EPS beat(16)-1.53%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)2
Avg Revenue beat(8)-32.42%
Revenue beat(12)4
Avg Revenue beat(12)-16.52%
Revenue beat(16)6
Avg Revenue beat(16)-17.87%
PT rev (1m)0.99%
PT rev (3m)-1.01%
EPS NQ rev (1m)-1.44%
EPS NQ rev (3m)-17.56%
EPS NY rev (1m)-3.37%
EPS NY rev (3m)-19.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-17.5%
Revenue NY rev (3m)-76.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.04
P/tB 3.14
EV/EBITDA N/A
EPS(TTM)-4
EYN/A
EPS(NY)-5.18
Fwd EYN/A
FCF(TTM)-3.05
FCFYN/A
OCF(TTM)-2.99
OCFYN/A
SpS0
BVpS12.16
TBVpS11.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.46%
ROE -26.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.08%
ROA(5y)-24.01%
ROE(3y)-28.89%
ROE(5y)-28.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 135.13%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.2
Quick Ratio 14.2
Altman-Z 13.27
F-Score3
WACC9.55%
ROIC/WACCN/A
Cap/Depr(3y)158.77%
Cap/Depr(5y)142.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.43%
EPS Next Y-34.75%
EPS Next 2Y-20.48%
EPS Next 3Y-10.66%
EPS Next 5Y21.33%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year350%
Revenue Next 2Y291.95%
Revenue Next 3Y670.52%
Revenue Next 5Y450.85%
EBIT growth 1Y-41.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-46.62%
EBIT Next 3Y-17.47%
EBIT Next 5Y11.15%
FCF growth 1Y-58.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-59.01%
OCF growth 3YN/A
OCF growth 5YN/A